CKPT is a subsidiary of FBIO with a pipeline of me-too oncology assets Lead program is CK-101. It's presently in a Ph1/2 trial. It would compete with AZN's Tagrisso based on a better safety profile. CK-301 Ph1 results in lung cancer will be read out by EOY/18 Cash runway is into Q2/2019.